238 related articles for article (PubMed ID: 35623884)
1. Lysosomal lipid switch sensitises to nutrient deprivation and mTOR targeting in pancreatic cancer.
De Santis MC; Gozzelino L; Margaria JP; Costamagna A; Ratto E; Gulluni F; Di Gregorio E; Mina E; Lorito N; Bacci M; Lattanzio R; Sala G; Cappello P; Novelli F; Giovannetti E; Vicentini C; Andreani S; Delfino P; Corbo V; Scarpa A; Porporato PE; Morandi A; Hirsch E; Martini M
Gut; 2023 Feb; 72(2):360-371. PubMed ID: 35623884
[TBL] [Abstract][Full Text] [Related]
2. HIF-2α regulates non-canonical glutamine metabolism via activation of PI3K/mTORC2 pathway in human pancreatic ductal adenocarcinoma.
Li W; Chen C; Zhao X; Ye H; Zhao Y; Fu Z; Pan W; Zheng S; Wei L; Nong T; Li Z; Chen R
J Cell Mol Med; 2017 Nov; 21(11):2896-2908. PubMed ID: 28544376
[TBL] [Abstract][Full Text] [Related]
3. The suppressive efficacy of THZ1 depends on KRAS mutation subtype and is associated with super-enhancer activity and the PI3K/AKT/mTOR signalling in pancreatic ductal adenocarcinoma: A hypothesis-generating study.
Huang L; Yang H; Chen K; Yuan J; Li J; Dai G; Gu M; Shi Y
Clin Transl Med; 2023 Dec; 13(12):e1500. PubMed ID: 38037549
[TBL] [Abstract][Full Text] [Related]
4. Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer.
Mortazavi M; Moosavi F; Martini M; Giovannetti E; Firuzi O
Crit Rev Oncol Hematol; 2022 Aug; 176():103749. PubMed ID: 35728737
[TBL] [Abstract][Full Text] [Related]
5. Efemp1 and p27(Kip1) modulate responsiveness of pancreatic cancer cells towards a dual PI3K/mTOR inhibitor in preclinical models.
Diersch S; Wenzel P; Szameitat M; Eser P; Paul MC; Seidler B; Eser S; Messer M; Reichert M; Pagel P; Esposito I; Schmid RM; Saur D; Schneider G
Oncotarget; 2013 Feb; 4(2):277-88. PubMed ID: 23470560
[TBL] [Abstract][Full Text] [Related]
6. Increased Serotonin Signaling Contributes to the Warburg Effect in Pancreatic Tumor Cells Under Metabolic Stress and Promotes Growth of Pancreatic Tumors in Mice.
Jiang SH; Li J; Dong FY; Yang JY; Liu DJ; Yang XM; Wang YH; Yang MW; Fu XL; Zhang XX; Li Q; Pang XF; Huo YM; Li J; Zhang JF; Lee HY; Lee SJ; Qin WX; Gu JR; Sun YW; Zhang ZG
Gastroenterology; 2017 Jul; 153(1):277-291.e19. PubMed ID: 28315323
[TBL] [Abstract][Full Text] [Related]
7. Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1/GSK-3 pathway inhibitors, nutraceuticals and alter metabolic properties.
McCubrey JA; Meher AK; Akula SM; Abrams SL; Steelman LS; LaHair MM; Franklin RA; Martelli AM; Ratti S; Cocco L; Barbaro F; Duda P; Gizak A
Aging (Albany NY); 2022 Apr; 14(8):3365-3386. PubMed ID: 35477123
[TBL] [Abstract][Full Text] [Related]
8. Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer.
Totiger TM; Srinivasan S; Jala VR; Lamichhane P; Dosch AR; Gaidarski AA; Joshi C; Rangappa S; Castellanos J; Vemula PK; Chen X; Kwon D; Kashikar N; VanSaun M; Merchant NB; Nagathihalli NS
Mol Cancer Ther; 2019 Feb; 18(2):301-311. PubMed ID: 30404927
[TBL] [Abstract][Full Text] [Related]
9. MTOR inhibitor-based combination therapies for pancreatic cancer.
Hassan Z; Schneeweis C; Wirth M; Veltkamp C; Dantes Z; Feuerecker B; Ceyhan GO; Knauer SK; Weichert W; Schmid RM; Stauber R; Arlt A; Krämer OH; Rad R; Reichert M; Saur D; Schneider G
Br J Cancer; 2018 Feb; 118(3):366-377. PubMed ID: 29384525
[TBL] [Abstract][Full Text] [Related]
10. Phosphoglycerate Mutase 1 (PGAM1) Promotes Pancreatic Ductal Adenocarcinoma (PDAC) Metastasis by Acting as a Novel Downstream Target of the PI3K/Akt/mTOR Pathway.
Liu X; Tan X; Liu P; Wu Y; Qian S; Zhang X
Oncol Res; 2018 Aug; 26(7):1123-1131. PubMed ID: 29386088
[TBL] [Abstract][Full Text] [Related]
11. Targeting mTOR dependency in pancreatic cancer.
Morran DC; Wu J; Jamieson NB; Mrowinska A; Kalna G; Karim SA; Au AY; Scarlett CJ; Chang DK; Pajak MZ; ; Oien KA; McKay CJ; Carter CR; Gillen G; Champion S; Pimlott SL; Anderson KI; Evans TR; Grimmond SM; Biankin AV; Sansom OJ; Morton JP
Gut; 2014 Sep; 63(9):1481-9. PubMed ID: 24717934
[TBL] [Abstract][Full Text] [Related]
12. Transcriptome data-based status of PI3K/AKT/mTOR pathway indicates heterogeneity and immune modulation in patients with pancreatic ductal adenocarcinoma.
Xie P; Tan SY; Li HF; Tang HD; Zhou JH
J Gene Med; 2024 Jan; 26(1):e3570. PubMed ID: 37482968
[TBL] [Abstract][Full Text] [Related]
13. Protein kinase N controls a lysosomal lipid switch to facilitate nutrient signalling via mTORC1.
Wallroth A; Koch PA; Marat AL; Krause E; Haucke V
Nat Cell Biol; 2019 Sep; 21(9):1093-1101. PubMed ID: 31451768
[TBL] [Abstract][Full Text] [Related]
14. The Inhibitory Response to PI3K/AKT Pathway Inhibitors MK-2206 and Buparlisib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines.
Ma Y; Sender S; Sekora A; Kong W; Bauer P; Ameziane N; Al-Ali R; Krake S; Radefeldt M; Weiss FU; Lerch MM; Parveen A; Zechner D; Junghanss C; Murua Escobar H
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457111
[TBL] [Abstract][Full Text] [Related]
15. Macropinocytosis Renders a Subset of Pancreatic Tumor Cells Resistant to mTOR Inhibition.
Michalopoulou E; Auciello FR; Bulusu V; Strachan D; Campbell AD; Tait-Mulder J; Karim SA; Morton JP; Sansom OJ; Kamphorst JJ
Cell Rep; 2020 Feb; 30(8):2729-2742.e4. PubMed ID: 32101748
[TBL] [Abstract][Full Text] [Related]
16. PORCN inhibition synergizes with PI3K/mTOR inhibition in Wnt-addicted cancers.
Zhong Z; Sepramaniam S; Chew XH; Wood K; Lee MA; Madan B; Virshup DM
Oncogene; 2019 Oct; 38(40):6662-6677. PubMed ID: 31391551
[TBL] [Abstract][Full Text] [Related]
17. Glycolysis-non-canonical glutamine dual-metabolism regulation nanodrug enhanced the phototherapy effect for pancreatic ductal adenocarcinoma treatment.
Qiao J; Liu S; Huang Y; Zhu X; Xue C; Wang Y; Xiong H; Yao J
J Colloid Interface Sci; 2024 Jul; 665():477-490. PubMed ID: 38429120
[TBL] [Abstract][Full Text] [Related]
18. BRSK2 induced by nutrient deprivation promotes Akt activity in pancreatic cancer via downregulation of mTOR activity.
Saiyin H; Na N; Han X; Fang Y; Wu Y; Lou W; Yang X
Oncotarget; 2017 Jul; 8(27):44669-44681. PubMed ID: 28591720
[TBL] [Abstract][Full Text] [Related]
19. Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancer.
Ning C; Liang M; Liu S; Wang G; Edwards H; Xia Y; Polin L; Dyson G; Taub JW; Mohammad RM; Azmi AS; Zhao L; Ge Y
Oncotarget; 2017 Jul; 8(27):44295-44311. PubMed ID: 28574828
[TBL] [Abstract][Full Text] [Related]
20. The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer.
Awasthi N; Yen PL; Schwarz MA; Schwarz RE
J Cell Biochem; 2012 Mar; 113(3):784-91. PubMed ID: 22020918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
